Clinical trials: Pancreatic Cancer Stage
Pancreatic Neoplasms
Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
<Part I - Phase I trial> The phase I clinical trial is to identify the MTD (Maximum Tolerated Dose) and DLT (Dose Limiting Toxicity) of CG200745 PPA in combination use of Gemcitabine and Erlotinib.
- Trial name
- NCT02737228
- Testing
- CG200745 PPA, Gemcitabine, Erlotinib
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- CrystalGenomics, Inc.
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma
Cardiovascular diseases and cancers, the two leading causes of death in Canada, require cholesterol to sustain their progression.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer, Metastatic Cancer
- Trial name
- NCT04862260
- Testing
- Cholesterol metabolism disruption
- Where
- 2 sites in Canada
- Volunteers
- 3 people
- Sponsor
- CHU de Quebec-Universite Laval
Pancreatic Cancer, Melanoma
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
An immunotherapy study combining ipilimumab and evofosfamide for the treatment of patients with confirmed metastatic or locally advanced prostate cancer, metastatic pancreatic cancer, melanoma or human papillomavirus (HPV)…
- Conditions
- Pancreatic Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Prostate Cancer
- Trial name
- NCT03098160
- Testing
- Evofosfamide, Ipilimumab
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Threshold Pharmaceuticals
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA)
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.
- Trial name
- NCT06984562
- Testing
- Adaptive Radiation Therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Fox Chase Cancer Center
Solid Tumors, Advanced Cancer
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
To assess: efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion…
- Conditions
- Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer
- Trial name
- SPARTA (NCT03175224)
- Testing
- APL-101 Oral Capsules
- Where
- 35 sites in United States, Australia and 9 more
- Volunteers
- 497 people
- Sponsor
- Apollomics Inc.
Pancreatic Cancer
Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
This study tests the combination of two targeted therapies,along with chemotherapy treatment in the treatment of pancreatic cancer.
- Trial name
- NCT00696696
- Testing
- Gemcitabine, Erlotinib, Sorafenib
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- NYU Langone Health
Pancreatic Adenocarcinoma, Pancreatic Cancer
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
This is a phase 1, first in human, dose escalation study for safety and feasibility of multi-dose dendritic cell (DC) therapy for pancreatic ductal adenocarcinoma (PDAC) including adenosquamous carcinoma administered after…
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenosquamous Carcinoma
- Trial name
- DECIST (NCT04157127)
- Testing
- Autologous DC Therapy
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Diakonos Oncology Corporation
Pancreatic Ductal Adenocarcinoma
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
The purpose of this study is to evaluate the safety and efficacy of abemaciclib alone and in combination with other drugs versus standard of care in participants with previously treated metastatic pancreatic ductal adenocarcinoma…
- Trial name
- NCT02981342
- Testing
- Abemaciclib, LY3023414, Gemcitabine
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 106 people
- Sponsor
- Eli Lilly and Company
Pancreatic Cancer Stage I, Pancreatic Cancer Stage II
Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer
This is a case-control study to clinically validate the performance of a protein biomarker test to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired from control…
- Conditions
- Pancreatic Cancer Stage I, Pancreatic Cancer Stage II, Cancer Diagnosis, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- CLARITI (NCT06947382)
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 1,066 people, healthy volunteers welcome
- Sponsor
- Immunovia, Inc.
Metastatic Pancreatic Carcinoma
Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer
The purpose of this study is to find out what activity the combination of docetaxel and Iressa have against metastatic pancreatic cancer.
- Trial name
- NCT00137761
- Testing
- ZD 1839, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Neuroendocrine Carcinomas (NEC), Neuroendocrine Carcinoma of Pancreas
Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients
This is a phase 2 single-arm, open-label clinical trial designed to evaluate the efficacy and safety of tarlatamab in patients with relapsed extrapulmonary neuroendocrine carcinoma (EPNEC) who have previously received…
- Conditions
- Neuroendocrine Carcinomas (NEC), Neuroendocrine Carcinoma of Pancreas, Neuroendocrine Carcinoma of Prostate
- Trial name
- DeLLight (NCT06893783)
- Testing
- Tarlatamab
- Where
- 4 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Inkeun Park
Pancreatic Cancer, Pancreatic Adenocarcinoma
Predicting Effective Therapy in Pancreatic Cancer
The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.
- Trial name
- NCT03033927
- Testing
- CTC isolocation and analysis
- Where
- 4 sites in United States
- Volunteers
- 74 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Adenocarcinoma
Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy
The main purpose of this study is to look at the effectiveness, safety, and anti-tumor activity (preventing growth of the tumor) of the drugs Niraparib with either Ipilimumab or Nivolumab on patients and their pancreatic cancer.
- Trial name
- Parpvax (NCT03404960)
- Testing
- Niraparib + Nivolumab, Niraparib + Ipilimumab
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- University of Pennsylvania
Pancreatic Cancer
PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen
The objectives of this multi-center, randomized, controlled trial are to evaluate the safety and efficacy of PANVAC-VF in combination with Granulocyte-macrophage colony-stimulating factor (GM-CSF) versus best supportive care or…
- Trial name
- NCT00088660
- Testing
- PANVAC™-VF
- Where
- 62 sites in United States
- Volunteers
- 250 people
- Sponsor
- Therion Biologics Corporation
Pancreatic Cancer Stage II, Pancreatic Cancer Stage III
Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)
This study is for patients with locally advanced pancreatic cancer (cancer that involves the local blood vessels so it cannot be removed without cutting major blood vessels) that cannot be treated with surgery.
- Trial name
- NCT01065870
- Testing
- Neoadjuvant gemcitabine, capecitabine, and docetaxel, Gemcitabine, capecitabine, docetaxel followed by radiotherapy
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Columbia University
Breast Cancer, Lung Cancer
18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer
The primary objective of the trial is to test the new radio tracer 18F-ASIS for PET imaging of tissue factor (TF) expression. The tracer has the potential of identifying tumors with high levels of TF expression, which is expected…
- Conditions
- Breast Cancer, Lung Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT03790423
- Testing
- Injection of 18F-ASIS, PET/CT scan
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Advanced Pancreatic Cancer
A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer
This is a randomized, double-blind, multi-center, phase III study to evaluate the efficacy and safety, pharmacokinetic profile and immunogenicity of MRG004A in patients with advanced pancreatic cancer.
- Trial name
- NCT07138846
- Testing
- MRG004A plus best supportive care
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Pancreatic Cancer
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
The purpose of this study is to investigate the activity of MORAb-009 when added to a standard regimen of gemcitabine in patients with previously untreated unresectable stage 3 or 4 pancreatic cancer.
- Trial name
- NCT00570713
- Testing
- MORAb-009, Gemcitabine
- Where
- 45 sites in United States, Belgium and 3 more
- Volunteers
- 155 people
- Sponsor
- Morphotek
Pancreatic Cancer, Metastatic Pancreatic Cancer
Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
Pancreatic cancer is one of the leading causes of cancer deaths in the United States with limited treatment options, especially for those patients with metastatic disease.
- Trial name
- NCT04820179
- Testing
- Cabozantinib + Atezolizumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Arizona
Advance Pancreatic Cancer
QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer
The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 80 patients with advanced pancreatic cancer who have not received prior treatment.
- Trial name
- NCT07110064
- Testing
- QL1706+Lenvatinib+AG Regimen
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Du Juan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.